Analyst Price Targets — LYEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 10:00 am | — | Needham | $44.00 | $23.79 | TheFly | Lyell Immunopharma initiated with a Buy at Needham |
| December 9, 2025 11:14 am | — | H.C. Wainwright | $45.00 | $28.36 | TheFly | Lyell Immunopharma upgraded to Buy from Neutral at H.C. Wainwright |
| November 24, 2025 11:15 am | — | H.C. Wainwright | $20.00 | $19.13 | TheFly | Lyell Immunopharma price target raised to $20 from $10 at H.C. Wainwright |
| October 30, 2024 6:05 am | Geoff Meacham | Bank of America Securities | $1.00 | $0.95 | TheFly | Lyell Immunopharma downgraded to Underperform from Buy at BofA |
| November 14, 2022 6:18 am | — | Morgan Stanley | $7.00 | $4.53 | Benzinga | Morgan Stanley Downgrades Lyell Immunopharma to Equal-Weight, Lowers Price Target to $7 |
| May 24, 2022 10:09 am | — | Goldman Sachs | $12.00 | $4.01 | Benzinga | Goldman Sachs Maintains Buy on Lyell Immunopharma, Lowers Price Target to $12 |
Latest News for LYEL
Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 1,138,296 shares, an increase of 21.1% from the March 15th total of 940,269 shares. Currently, 6.3% of the company's stock are short sold. Based on an
Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14,…
Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lyell Immunopharma (NASDAQ: LYEL - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations. Profitability This table compares Mangoceuticals and Lyell…
Lyell Immunopharma is a CAR-T developer with a single pivotal asset, ronde-cel, targeting LBCL and showing superior early efficacy and safety data. Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3L+ LBCL patients outperformed approved peers, supporting a $1B+ peak sales opportunity. Valuation estimates suggest LYEL equity value of ~$45–55 per share, with the current price reflecting moderate success probability;…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LYEL.
U.S. House Trading
No House trades found for LYEL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.